At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 716 enrolled
Drug / intervention
PriorixTetra™ +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children
In Brief
A Phase 3 clinical trial evaluating PriorixTetra™ and Meningitec for Rubella and 3 related conditions. Completed, enrolled 716 participants across 13 sites.
Detailed Summary
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' investigational measles, mumps, rubella and varicella (MMRV) vaccine (GSK208136, PriorixTetra™) when co-administered along with conjugated Meningococcal C (MenC) vaccine (Meningitec®, Nuron Biotechs' Vaccine) in healthy children.
Study Details
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartFeb 2012
Primary CompletionFeb 2014
Study CompletionMar 2014
TodayJul 2026
First PostedJan 9, 2012
Enrollment StartFeb 6, 2012
Primary CompletionFeb 17, 2014
Study CompletionMar 31, 2014
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 14.5 years ago
Interventions
PriorixTetra™biological
One dose administered subcutaneously
Meningitecbiological
One dose administered intramuscularly